Figure 2: M31 overexpression enhances PEV when the transgene is pericentromeric. Figure 4: M31 overexpression suppresses PEV when the transgene is in a non-centromeric location. We generated all ...
Comparison of dose modification strategies to address expected hematologic toxicities in treatment-naïve higher-risk (HR) MDS patients treated with venetoclax + azacitidine. This is an ASCO Meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results